Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11379065 | 0.87 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1ALDH1A1L3MBTL1 | |
| SCHEMBL11377985 | 0.86 | PTGS1 (0.50) | PTPN1RAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL11384353 | 0.85 | MEN1 (0.43) | RAB9ASMN1; SMN2NPC1TP53ALDH1A1 | |
| SCHEMBL10668168 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1ALDH1A1LMNAMAPT | |
| SCHEMBL4232 | 0.85 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1TP53ALDH1A1 | |
| SCHEMBL11384572 | 0.83 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2NPC1TP53ALDH1A1 | |
| SCHEMBL10665627 | 0.82 | TRPV1 (0.55) | TRPV1MAPT | |
| SCHEMBL27868823 | 0.81 | SMN1; SMN2 (0.40) | PTPN1RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL11381671 | 0.81 | AR (0.41) | RAB9ATP53ALDH1A1MAPK1LMNA | |
| SCHEMBL1563 | 0.80 | PTPN1 (0.47) | PTPN1RAB9ASMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2014-09-11 | — | — | US | disclosed |
| US-8778983-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2438048-B1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | PTPN1 931/4885RAB9A 2536/4885SMN1; SMN2 4422/4885 |
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | PTPN1 931/4885RAB9A 2536/4885SMN1; SMN2 4422/4885 |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | PTPN1 931/4885RAB9A 2536/4885SMN1; SMN2 4422/4885 |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR4 | PTPN1 931/4885RAB9A 2536/4885SMN1; SMN2 4422/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PTPN1 898/4885RAB9A 2824/4885SMN1; SMN2 4481/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PTPN1 898/4885RAB9A 2824/4885SMN1; SMN2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.